Trinity Biotech reported the receipt of a formal notification from The Nasdaq Stock Market that the company has regained compliance with Listing Rule 5450(a)(1), which requires the company’s American Depositary Shares, or ADSs, to maintain a minimum bid price of $1.00 per ADS. Nasdaq considers the prior bid price deficiency matter now closed, the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TRIB:
- Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
- Trinity Biotech trading halted, news pending
- Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change
- Trinity Biotech announces plan to implement ADS ratio change
- Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change